Journal of liver cancer最新文献_第2页

Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma. 探索肝切除术作为多结节 BCLC-A 型肝癌一线治疗方案的作用。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.17998/jlc.2024.08.08

Joo Hyun Oh, Dong Hyun Sinn

引用次数: 0

Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis. 质子束疗法治疗肝细胞癌的最新进展：系统回顾和荟萃分析。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.17998/jlc.2024.06.26

Sun Hyun Bae, Won Il Jang, Hanna Rahbek Mortensen, Britta Weber, Mi Sook Kim, Morten Høyer

{"title":"Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis.","authors":"Sun Hyun Bae, Won Il Jang, Hanna Rahbek Mortensen, Britta Weber, Mi Sook Kim, Morten Høyer","doi":"10.17998/jlc.2024.06.26","DOIUrl":"10.17998/jlc.2024.06.26","url":null,"abstract":"Backgrounds/aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"286-302"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study. 2008年至2022年韩国肝细胞癌治疗模式的演变趋势：一项基于全国人口的研究。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-26 DOI: 10.17998/jlc.2024.08.13

Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi

{"title":"Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study.","authors":"Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi","doi":"10.17998/jlc.2024.08.13","DOIUrl":"10.17998/jlc.2024.08.13","url":null,"abstract":"Backgrounds/aims: The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database from the Korean Health Insurance Review and Assessment Service.Methods: This retrospective population-based cohort study analyzed 171,002 newly diagnosed HCC patients between 2008 and 2022. Etiologies and treatment modalities were categorized based on the ICD-10 codes and insurance data.Results: The annual incidence decreased from 11,814 in 2008 to 10,443 in 2022. However, patients aged ≥70 increased noticeably, with those aged ≥80 rising from 3.8% in 2008 to 13.1% in 2022. From 2008 to 2022, the predominant cause of hepatitis B virus decreased from 68.9% to 59.7%, whereas nonalcoholic fatty liver disease increased from 8.9% to 15.8%. The initial treatment trends shifted: surgical resection and systemic therapy increased from 12.2% to 21.3% and from 0.2% to 9.6%, whereas transarterial therapy decreased from 49.9% to 36.6%. Best supportive care decreased from 31.7% to 21.3%. In the subgroup analysis, laparoscopic resection rate increased from 10.6% to 60.6% among the surgical resections. Sorafenib initially accounted for 100%, lenvatinib peaked at 36.5% in 2021, and atezolizumab-bevacizumab became the most widely used (63.1%) by 2022 among the systemic therapies.Conclusions: This study demonstrates the temporal changes in the treatment patterns of Korean HCC patients. Surgical resection, particularly laparoscopic liver resection, and systemic therapy has increased significantly. These changes may have been influenced by reimbursement policies and advances in clinical research.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"274-285"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases. 局部区域疗法在治疗肝细胞癌肝外转移中的地位。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-29 DOI: 10.17998/jlc.2024.08.26

Beom Kyung Kim

引用次数: 0

Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging. 重新评估肝细胞癌成像中增强 "囊 "的诊断价值。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-05-08 DOI: 10.17998/jlc.2024.05.01

Jae Seok Bae, Jeong Min Lee, Bo Yun Hur, Jeongin Yoo, Sae-Jin Park

{"title":"Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging.","authors":"Jae Seok Bae, Jeong Min Lee, Bo Yun Hur, Jeongin Yoo, Sae-Jin Park","doi":"10.17998/jlc.2024.05.01","DOIUrl":"10.17998/jlc.2024.05.01","url":null,"abstract":"Backgrounds/aims: The enhancing capsule (EC) in hepatocellular carcinoma (HCC) diagnosis has received varying degrees of recognition across major guidelines. This study aimed to assess the diagnostic utility of EC in HCC detection.Methods: We retrospectively analyzed patients who underwent pre-surgical computed tomography (CT) and hepatobiliary agent-enhanced magnetic resonance imaging (HBA-MRI) between January 2016 and December 2019. A single hepatic tumor was confirmed based on the pathology of each patient. Three radiologists independently reviewed the images according to the Liver Imaging Reporting and Data System (LI-RADS) v2018 criteria and reached a consensus. Interobserver agreement for EC before reaching a consensus was quantified using Fleiss κ statistics. The impact of EC on the LI-RADS classification was assessed by comparing the positive predictive values for HCC detection in the presence and absence of EC.Results: In total, 237 patients (median age, 60 years; 184 men) with 237 observations were included. The interobserver agreement for EC detection was notably low for CT (κ=0.169) and HBA-MRI (κ=0.138). The presence of EC did not significantly alter the positive predictive value for HCC detection in LI-RADS category 5 observations on CT (94.1% [80/85] vs. 94.6% [88/93], P=0.886) or HBAMRI (95.7% [88/92] vs. 90.6% [77/85], P=0.178).Conclusions: The diagnostic value of EC in HCC diagnosis remains questionable, given its poor interobserver agreement and negligible impact on positive predictive values for HCC detection. This study challenges the emphasis on EC in certain diagnostic guidelines and suggests the need to re-evaluate its role in HCC imaging.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"206-216"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inter-reader agreement for LR-M imaging features: a premise for better imaging-based diagnosis in liver imaging. LR-M 成像特征的读片者间一致性：肝脏成像中更好的成像诊断前提。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.17998/jlc.2024.08.06

Jaeseung Shin

引用次数: 0

Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma. 与 HBV 相关的 HCC 中的疾病调节因子和新型标记物。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.17998/jlc.2024.08.03

Lung-Yi Mak

{"title":"Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma.","authors":"Lung-Yi Mak","doi":"10.17998/jlc.2024.08.03","DOIUrl":"10.17998/jlc.2024.08.03","url":null,"abstract":"Chronic hepatitis B (CHB) infection is responsible for 40% of the global burden of hepatocellular carcinoma (HCC) with a high case fatality rate. The risk of HCC differs among CHB subjects owing to differences in host and viral factors. Modifiable risk factors include viral load, use of antiviral therapy, co-infection with other hepatotropic viruses, concomitant metabolic dysfunctionassociated steatotic liver disease or diabetes mellitus, environmental exposure, and medication use. Detecting HCC at early stage improves survival, and current practice recommends HCC surveillance among individuals with cirrhosis, family history of HCC, or above an age cut-off. Ultrasonography with or without serum alpha feto-protein (AFP) every 6 months is widely accepted strategy for HCC surveillance. Novel tumor-specific markers, when combined with AFP, improve diagnostic accuracy than AFP alone to detect HCC at an early stage. To predict the risk of HCC, a number of clinical risk scores have been developed but none of them are clinically implemented nor endorsed by clinical practice guidelines. Biomarkers that reflect viral transcriptional activity and degree of liver fibrosis can potentially stratify the risk of HCC, especially among subjects who are already on antiviral therapy. Ongoing exploration of these novel biomarkers is required to confirm their performance characteristics, replicability and practicability.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"145-154"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association. 肝细胞癌局部消融术：韩国肝癌协会基于专家共识的 2024 年实用建议。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.17998/jlc.2024.08.04

Seungchul Han, Pil Soo Sung, Soo Young Park, Jin Woong Kim, Hyun Pyo Hong, Jung-Hee Yoon, Dong Jin Chung, Joon Ho Kwon, Sanghyeok Lim, Jae Hyun Kim, Seung Kak Shin, Tae Hyung Kim, Dong Ho Lee, Jong Young Choi

{"title":"Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association.","authors":"Seungchul Han, Pil Soo Sung, Soo Young Park, Jin Woong Kim, Hyun Pyo Hong, Jung-Hee Yoon, Dong Jin Chung, Joon Ho Kwon, Sanghyeok Lim, Jae Hyun Kim, Seung Kak Shin, Tae Hyung Kim, Dong Ho Lee, Jong Young Choi","doi":"10.17998/jlc.2024.08.04","DOIUrl":"10.17998/jlc.2024.08.04","url":null,"abstract":"Local ablation for hepatocellular carcinoma (HCC), a non-surgical option that directly targets and destroys tumor cells, has advanced significantly since the 1990s. Therapies with different energy sources, such as radiofrequency ablation, microwave ablation, and cryoablation, employ different mechanisms to induce tumor necrosis. The precision, safety, and effectiveness of these therapies have increased with advances in guiding technologies and device improvements. Consequently, local ablation has become the firstline treatment for early-stage HCC. The lack of organized evidence and expert opinions regarding patient selection, pre-procedure preparation, procedural methods, swift post-treatment evaluation, and follow-up has resulted in clinicians following varied practices. Therefore, an expert consensus-based practical recommendation for local ablation was developed by a group of experts in radiology and hepatology from the Research Committee of the Korean Liver Cancer Association in collaboration with the Korean Society of Image-guided Tumor Ablation to provide useful information and guidance for performing local ablation and for the pre- and posttreatment management of patients.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"131-144"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congratulatory remarks. 祝贺词。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-09-13 DOI: 10.17998/jlc.2024.09.10

Kyung Sik Kim

引用次数: 0

Practical consensus multi-specialty guidelines on image-guided ablation for hepatocellular carcinoma. 图像引导下肝细胞癌消融多专科实用共识指南。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-09-27 DOI: 10.17998/jlc.2024.09.11

David S Lu

引用次数: 0